We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 18, 2024 – Stocks in this week’s article are ADMA Biologics Inc. (ADMA - Free Report) , American Superconductor Corp. (AMSC - Free Report) , biote Corp. (BTMD - Free Report) , Lincoln Educational Services Corp. (LINC - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) .
5 Stocks with Recent Price Strength to Tap Wall Street Rally
Wall Street is witnessing an impressive broad-based rally in July following a significant boost in investors’ confidence in a September rate cut. Aside from large caps, beaten-down small-cap stocks are also participating in this rally. Consequently, a few stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. Such stocks have a high chance of carrying the momentum forward.
If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.
Here’s how you should create the screen to shortlist the current as well as the potential winners.
Just these few criteria narrowed down the search from over 7,700 stocks to 13.
Let’s discuss five out of these 13 stocks:
ADMA Biologics Inc. is a specialty immune globulin company. ADMA develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases.
ADMA’s target patient populations include immune-compromised individuals suffering from an underlying immune deficiency disease or are immune-suppressed for medical reasons. ADMA’s lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease.
The stock price of ADMA Biologics has soared 29.3% in the past four weeks. It has an expected earnings growth rate of more than 100% for next year. The Zacks Consensus Estimate for current-year earnings has improved 16.7% over the last 90 days.
American Superconductor Corp. develops and sells a wide range of products and solutions based on power electronic systems and high-temperature superconductor wires that dramatically improve the efficiency, reliability and quality of electricity during its generation, transmission, distribution and use.
AMSC is a dominant force in alternative energy, offering grid interconnection solutions as well as licensed wind energy designs and electrical systems. As the world's principal supplier of HTS wire, AMSC is enabling a new generation of compact, high-power electrical products, including power cables, grid-level surge protectors, motors, generators, and advanced transportation and defense systems.
The stock price of American Superconductor has jumped 28.8% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year (ending March 2025). The Zacks Consensus Estimate for current-year earnings has improved 66.7% over the last 60 days.
biote Corp. in practice-building business within the hormone optimization space. BTMD trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
BTMD offers Biote Method, a comprehensive end-to-end practice-building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services.
The stock price of biote has climbed 27.6% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3.8% over the last 30 days.
Lincoln Educational Services Corp. provides various career-oriented post-secondary education services to high school graduates and working adults in the United States. LINC operates in two segments, Campus Operations and Transitional.
LINC offers associate's degree, and diploma and certificate programs in automotive technology, health science programs, hospitality service and information technology programs. LINC operates schools under the Lincoln Technical Institute, Lincoln College of Technology, Lincoln Culinary Institute, Euphoria Institute of Beauty Arts and Sciences, and other brand names.
The stock price of Lincoln Educational Services has surged 27% in the past four weeks. It has an expected earnings growth rate of 35.4% for next year. The Zacks Consensus Estimate for current-year earnings improved 20.4% over the last 30 days.
Corcept Therapeutics Inc. is engaged in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. CORT offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome, and for those who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
CORT is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome, treatment for adrenal cancer and cortisol excess, which is in phase 1b clinical trial, treatment for prostate cancer which is in phase II clinical trial and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
The stock price of Corcept Therapeutics has rallied 18.4% in the past four weeks. It has an expected earnings growth rate of 1.1% for the current year. The Zacks Consensus Estimate for current-year earnings improved 3.3% over the last 90 days.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
For Immediate Release
Chicago, IL – July 18, 2024 – Stocks in this week’s article are ADMA Biologics Inc. (ADMA - Free Report) , American Superconductor Corp. (AMSC - Free Report) , biote Corp. (BTMD - Free Report) , Lincoln Educational Services Corp. (LINC - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) .
5 Stocks with Recent Price Strength to Tap Wall Street Rally
Wall Street is witnessing an impressive broad-based rally in July following a significant boost in investors’ confidence in a September rate cut. Aside from large caps, beaten-down small-cap stocks are also participating in this rally.
Consequently, a few stocks have shown price strength. We have primarily targeted stocks that have recently been on a bull run. Such stocks have a high chance of carrying the momentum forward.
If a stock is continuously witnessing an uptrend, there must be a solid reason or it would have probably crashed. So, looking at stocks capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create magic. Therefore, other relevant parameters are needed to create a successful investment strategy.
Here’s how you should create the screen to shortlist the current as well as the potential winners.
Just these few criteria narrowed down the search from over 7,700 stocks to 13.
Let’s discuss five out of these 13 stocks:
ADMA Biologics Inc. is a specialty immune globulin company. ADMA develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases.
ADMA’s target patient populations include immune-compromised individuals suffering from an underlying immune deficiency disease or are immune-suppressed for medical reasons. ADMA’s lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease.
The stock price of ADMA Biologics has soared 29.3% in the past four weeks. It has an expected earnings growth rate of more than 100% for next year. The Zacks Consensus Estimate for current-year earnings has improved 16.7% over the last 90 days.
American Superconductor Corp. develops and sells a wide range of products and solutions based on power electronic systems and high-temperature superconductor wires that dramatically improve the efficiency, reliability and quality of electricity during its generation, transmission, distribution and use.
AMSC is a dominant force in alternative energy, offering grid interconnection solutions as well as licensed wind energy designs and electrical systems. As the world's principal supplier of HTS wire, AMSC is enabling a new generation of compact, high-power electrical products, including power cables, grid-level surge protectors, motors, generators, and advanced transportation and defense systems.
The stock price of American Superconductor has jumped 28.8% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year (ending March 2025). The Zacks Consensus Estimate for current-year earnings has improved 66.7% over the last 60 days.
biote Corp. in practice-building business within the hormone optimization space. BTMD trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
BTMD offers Biote Method, a comprehensive end-to-end practice-building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services.
The stock price of biote has climbed 27.6% in the past four weeks. It has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3.8% over the last 30 days.
Lincoln Educational Services Corp. provides various career-oriented post-secondary education services to high school graduates and working adults in the United States. LINC operates in two segments, Campus Operations and Transitional.
LINC offers associate's degree, and diploma and certificate programs in automotive technology, health science programs, hospitality service and information technology programs. LINC operates schools under the Lincoln Technical Institute, Lincoln College of Technology, Lincoln Culinary Institute, Euphoria Institute of Beauty Arts and Sciences, and other brand names.
The stock price of Lincoln Educational Services has surged 27% in the past four weeks. It has an expected earnings growth rate of 35.4% for next year. The Zacks Consensus Estimate for current-year earnings improved 20.4% over the last 30 days.
Corcept Therapeutics Inc. is engaged in the discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. CORT offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome, and for those who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
CORT is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome, treatment for adrenal cancer and cortisol excess, which is in phase 1b clinical trial, treatment for prostate cancer which is in phase II clinical trial and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
The stock price of Corcept Therapeutics has rallied 18.4% in the past four weeks. It has an expected earnings growth rate of 1.1% for the current year. The Zacks Consensus Estimate for current-year earnings improved 3.3% over the last 90 days.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2303154/5-stocks-with-recent-price-strength-to-tap-wall-street-rally
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.